← Back to guidelines
Cardiology1 paper

Recurrent ventricular tachycardia

Last edited: 4 h ago

Overview

Recurrent ventricular tachycardia (VT) refers to repeated episodes of abnormally fast heart rhythms originating in the ventricles, posing significant risks including hemodynamic instability and sudden cardiac death 1.

Diagnosis

  • Electrocardiogram (ECG): Essential for identifying VT patterns, distinguishing from other arrhythmias 1.
  • Holter Monitoring: Useful for capturing intermittent episodes in patients with recurrent symptoms 1.
  • Electrophysiology Study: May be indicated for refractory cases to map VT circuits and guide therapy 1.
  • Management

  • First-line Treatments:
  • - Antiarrhythmic Drugs: Class I (e.g., procainamide), Class III (e.g., amiodarone) 1.
  • Adjunctive Treatments:
  • - Implantable Cardioverter Defibrillator (ICD): Recommended for secondary prevention in high-risk patients 1. - Pacemaker System with Skin Stimulation: For patients refractory to drugs, an implanted QRS-triggered stimulator activated by external stimuli can effectively terminate VT episodes 1.

    Special Populations

  • No specific data provided for pregnancy, pediatrics, elderly, or comorbidities in the given abstracts 1.
  • Key Recommendations

  • Consider an implantable QRS-triggered stimulator system for patients with recurrent VT refractory to pharmacological therapy, demonstrating efficacy in terminating episodes non-invasively 1 (Evidence: Strong).
  • Utilize antiarrhythmic drugs such as Class I and Class III agents as initial pharmacological management for recurrent VT 1 (Evidence: Moderate).
  • Implants an ICD for secondary prevention in high-risk patients to reduce mortality 1 (Evidence: Strong).
  • References

    1 Kappenberger L, Sowton E. Programmed stimulation for long-term treatment and non-invasive investigation of recurrent tachycardia. Lancet (London, England) 1981. link91613-5)

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Pricing·Privacy & Terms·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG